Publications by authors named "Doug Conrad"

Background: Cystic fibrosis (CF) is a genetic disorder causing poor mucociliary clearance in the airways and subsequent respiratory infection. The recently approved triple therapy Elexacaftor-Tezacaftor-Ivacaftor (ETI) has significantly improved lung function and decreased airway infection in persons with CF (pwCF). This improvement has been shown to occur rapidly, within the first few weeks of treatment.

View Article and Find Full Text PDF
Article Synopsis
  • Cystic fibrosis (CF) is a genetic disorder that leads to respiratory issues, but recent triple therapy (Elexacaftor-Tezacaftor-Ivacaftor, or ETI) has shown rapid improvements in lung function and reduced infections in patients.
  • Researchers conducted a study using advanced techniques on sputum samples from CF patients on ETI therapy and those not receiving ETI, to compare lung function and infection dynamics over time.
  • Results indicated that lung function improved for those on ETI, and while microbiome and metabolome changes were individualized, a more dynamic microbial community was observed in treated subjects, highlighting the varied impacts of the therapy.
View Article and Find Full Text PDF

Background: Elexacaftor-Tezacaftor-Ivacaftor (ETI) therapy is showing promising efficacy for treatment of cystic fibrosis (CF) and is becoming more widely available since recent FDA approval. However, little is known about how these drugs will affect lung infections, which are the leading cause of morbidity and mortality among people with CF (pwCF).

Methods: We analyzed sputum microbiome and metabolome data from pwCF (n=24) before and after ETI therapy using 16S rRNA gene sequencing and untargeted metabolomics.

View Article and Find Full Text PDF

Background: Studies of the cystic fibrosis (CF) lung microbiome have consistently shown that lung function decline is associated with decreased microbial diversity due to the dominance of opportunistic pathogens. However, how this phenomenon is reflected in the metabolites and chemical environment of lung secretions remains poorly understood.

Methods: Here we investigated the microbial and molecular composition of CF sputum samples using 16S rRNA gene amplicon sequencing and untargeted tandem mass spectrometry to determine their interrelationships and associations with clinical measures of disease severity.

View Article and Find Full Text PDF

There is a poor understanding of how the physiology of polymicrobial communities in cystic fibrosis (CF) lungs contributes to pulmonary exacerbations and lung function decline. In this study, a microbial culture system based on the principles of the Winogradsky column (WinCF system) was developed to study the physiology of CF microbes. The system used glass capillary tubes filled with artificial sputum medium to mimic a clogged airway bronchiole.

View Article and Find Full Text PDF